Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
NeXT Personal Dx is an advanced blood test that helps you determine ahead of imaging or scans: if your current cancer treatment is working, if your cancer is still there after treatment or surgery, and if your cancer is likely to come back.1,5,6,7
Similar to your regular scan and blood tests, you can expect to give blood samples periodically for this test. This helps your doctor monitor the status of your cancer.
ctDNA Liquid Biopsy
As your body fights cancer, traces of DNA from cancer cells are released and flow (or “circulate”) in the bloodstream. Our blood test for cancer markers finds and measures the amount of circulating tumor DNA (ctDNA) in your blood.
Our ctDNA test can predict recurrence earlier than scans can show evidence of tumors, as much as ~3 years in some cases.7 This may allow your care team to optimize your treatment early and stay ahead of the disease.
In a study of patients with early-stage non-small cell lung cancer (NSCLC), NeXT Personal Dx detected recurrence, on median, about 6 months ahead of scans.1
In a study of patients with early-stage breast cancer, NeXT Personal Dx detected recurrence, on median, about 15 months ahead of scans.7
In a study of very sick patients with various late-stage metastatic cancers, NeXT Personal Dx detected progression, on average, about 3 months ahead of scans.8
NeXT Personal Dx has the power to help your oncology care team see early:
If ctDNA is detected or rising, your doctor may order additional scans. If you are on treatment while ctDNA is rising, your care team may update your treatment plan using this information.
Patients with repeat undetectable ctDNA were highly likely to remain cancer-free for years following the completion of treatment.1,7
Dr Nixon at Duke Cancer Institute researched ctDNA testing with NeXT Personal Dx. Based on his experience, Dr Nixon explains how NeXT Personal Dx testing could help clinicians stay ahead of cancer.
Circulating tumor DNA (ctDNA) are small fragments of DNA released from cancer cells into the bloodstream. NeXT Personal Dx can detect traces of ctDNA at very low levels in your blood, helping to monitor your cancer and response to treatment.
A negative NeXT Personal Dx result means no ctDNA was detected in your blood sample, and that there are no early molecular signs of cancer recurrence. A negative ctDNA result does not rule out the presence of ctDNA, and individuals who receive this result should continue following all treatment recommendations from their qualified health care providers.
Coverage for NeXT Personal Dx varies depending on your insurance plan. Personalis works with insurance providers to secure coverage for eligible patients. Personalis also offers a financial assistance program for qualifying patients.
PRO-1149-v1 (v1.1)
This test is a laboratory developed test (LDT) and is performed in the CAP accredited, CLIA-certified Personalis Clinical Laboratory. The test was developed, and its performance characteristics determined by the Personalis Clinical Laboratory. It has not been cleared or approved by the United States Food and Drug Administration (FDA).
